
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc has recently enhanced its financial stability through successful equity financings and option exercises, resulting in a significant increase in financing income to $284K for the quarter and $611K year-to-date. The company is poised for substantial growth with the impending launches of its LIBERTY Endovascular Robotic System in the US and EU, backed by a strengthened commercial infrastructure and positive provider feedback, which underscores the product's market potential. Furthermore, strategic partnerships with experienced logistics providers are set to streamline operations, indicating a robust foundation for future revenue acceleration as Microbot enters new markets.
Bears say
Microbot Medical faces significant risks that contribute to a negative outlook on its stock, including potential delays in commercializing its LIBERTY Endovascular Robotic System and challenges in expanding its application to cardio and neuro cases. The company is also confronted with reimbursement issues and a lack of near-term profitability, which may erode its financial stability. Additionally, the absence of robust data from randomized controlled trials and possible setbacks in obtaining international regulatory approvals further heighten the uncertainty surrounding its market adoption and sales potential.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares